# US 8,541,014 B2 · Gamma-tocopherol therapy for restenosis prevention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,014 B2
- Document ID: US8541014B2
- Status: Granted
- Kind: B2
- Application number: 13/357,208
- Filed: 2012-01-24
- Published: 2012-12-20
- Granted: 2013-09-24
- Earliest claimed: 2003-10-21
- Assignees: Celonova Biosciences, Inc.
- Applicants: James W. Larrick; James C. Peacock, III
- Inventors: James W. Larrick; James C. Peacock, III
- Web page: https://patentgrep.com/patent/US8541014B2

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/428: Vitamins, e.g. tocopherol, riboflavin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.

## Claims

### Claim 1

A drug eluting stent system, comprising: a stent; a tocopherol agent coupled to the stent; wherein said stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.

### Claim 2 (depends on 1)

The drug eluting stent system of claim 1 wherein said tocopherol agent is at least one of an agent selected from the group consisting of a des-methyl tocopherol agent, a gamma-tocopherol agent, a delta-tocopherol agent, a phytyl substituted chromanol agent, a gamma-tocotrienol agent, a delta-tocotrienol agent, or a precursor, analog, or derivative thereof.

### Claim 3 (depends on 1)

The drug eluting stent system of claim 1, further comprising: a porous metal carrier matrix; wherein said tocopherol agent is located principally within the porous metal carrier matrix and is adapted to elute therefrom into tissue in contact with said porous metal carrier matrix.

### Claim 4 (depends on 3)

The drug eluting stent system of claim 3, wherein said porous metal carrier matrix comprises an electrochemically deposited matrix.

### Claim 5 (depends on 1)

The drug eluting stent system of claim 1, further comprising a bioactive agent that is different from said tocopherol agent and that is adapted to be delivered into tissue in combination with said tocopherol agent.

### Claim 6 (depends on 5)

The drug eluting stent system of claim 5, wherein said bioactive agent comprises at least one agent selected from the group consisting of sirolimus, tacrolimus, everolimus, ABT-578, paclitaxel, dexamethasone, 17-beta-estradiol, steroid, des-aspartate angiotensin I (DAA-1), angiotensin converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor blocker, tachykinin, sialokinin, apocynin, pleiotrophin, exochelin, an iron chelator, VEGF, heparin, coumadin, clopidogrel, IIb/IIIa inhibitor, nitric oxide, a nitric oxide donor, an eNOS antagonist, a nitric oxide synthesis promoter, a statin, or a precursor, analog, or derivative thereof.